MY195369A - Vaccine Constructs and uses Thereof Against Staphylococcus Infections - Google Patents

Vaccine Constructs and uses Thereof Against Staphylococcus Infections

Info

Publication number
MY195369A
MY195369A MYPI2019002159A MYPI2019002159A MY195369A MY 195369 A MY195369 A MY 195369A MY PI2019002159 A MYPI2019002159 A MY PI2019002159A MY PI2019002159 A MYPI2019002159 A MY PI2019002159A MY 195369 A MY195369 A MY 195369A
Authority
MY
Malaysia
Prior art keywords
polypeptide
seq
amino acid
set forth
nos
Prior art date
Application number
MYPI2019002159A
Other languages
English (en)
Inventor
Francois Malouin
Celine Ster
Julie Cote-Gravel
Eric Brouillette
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of MY195369A publication Critical patent/MY195369A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019002159A 2016-10-21 2017-10-20 Vaccine Constructs and uses Thereof Against Staphylococcus Infections MY195369A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21
PCT/CA2017/051253 WO2018072031A1 (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections

Publications (1)

Publication Number Publication Date
MY195369A true MY195369A (en) 2023-01-16

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019002159A MY195369A (en) 2016-10-21 2017-10-20 Vaccine Constructs and uses Thereof Against Staphylococcus Infections

Country Status (24)

Country Link
US (2) US11324815B2 (https=)
EP (1) EP3529260A4 (https=)
JP (2) JP7181208B2 (https=)
KR (1) KR20190082229A (https=)
CN (1) CN109843910A (https=)
AR (1) AR109847A1 (https=)
AU (2) AU2017346974B2 (https=)
BR (1) BR112019007796A2 (https=)
CA (1) CA3037070A1 (https=)
CL (1) CL2019001048A1 (https=)
CO (1) CO2019005169A2 (https=)
CR (1) CR20190249A (https=)
DO (1) DOP2019000102A (https=)
IL (1) IL265869A (https=)
MX (2) MX2019004539A (https=)
MY (1) MY195369A (https=)
NZ (1) NZ751880A (https=)
PE (1) PE20191320A1 (https=)
PH (1) PH12019500843A1 (https=)
RU (2) RU2022100889A (https=)
SG (2) SG11201901483QA (https=)
TW (1) TW201819402A (https=)
UY (1) UY37448A (https=)
WO (1) WO2018072031A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777317A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
WO2022125928A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
WO2026014994A1 (ko) * 2024-07-12 2026-01-15 주식회사 더윤헬스텍 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288774C (en) 1985-01-07 1991-09-10 Deborah A. Eppstein 1,2-dialkoxy-w-trialkylammonium cationic surfactants
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) * 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
US8445000B2 (en) * 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
WO2006059846A1 (en) 2004-12-01 2006-06-08 Lg Life Sciences, Ltd. Formulation of sec1 mutated protein and method for formulation of the same
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
NZ614557A (en) * 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
MX2011010735A (es) * 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
SI2547361T1 (sl) 2010-03-17 2021-01-29 SOCPRA - Sceiences et Genie, s.e.c. Bakterijske komponente cepiva iz staphylococcus aureus in njihova uporaba
MX357938B (es) 2011-06-19 2018-07-31 Univ New York Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.

Also Published As

Publication number Publication date
US11324815B2 (en) 2022-05-10
SG11201901483QA (en) 2019-03-28
JP2023025066A (ja) 2023-02-21
CR20190249A (es) 2019-10-16
NZ751880A (en) 2023-04-28
RU2766354C2 (ru) 2022-03-15
RU2019115303A (ru) 2020-11-23
PE20191320A1 (es) 2019-09-24
MX2019004539A (es) 2019-06-12
US20190216913A1 (en) 2019-07-18
CO2019005169A2 (es) 2019-08-09
CL2019001048A1 (es) 2019-08-30
CN109843910A (zh) 2019-06-04
JP2019531100A (ja) 2019-10-31
IL265869A (en) 2019-06-30
PH12019500843A1 (en) 2019-12-02
SG10201912431XA (en) 2020-02-27
US20220288183A1 (en) 2022-09-15
RU2022100889A (ru) 2022-04-06
KR20190082229A (ko) 2019-07-09
BR112019007796A2 (pt) 2019-09-03
MX2023001219A (es) 2023-03-03
AU2017346974B2 (en) 2022-03-31
JP7181208B2 (ja) 2022-11-30
CA3037070A1 (en) 2018-04-26
EP3529260A4 (en) 2020-12-16
UY37448A (es) 2018-03-23
TW201819402A (zh) 2018-06-01
DOP2019000102A (es) 2019-07-15
AU2017346974A1 (en) 2019-03-14
RU2019115303A3 (https=) 2021-03-02
EP3529260A1 (en) 2019-08-28
AU2022204585A1 (en) 2022-07-21
AR109847A1 (es) 2019-01-30
WO2018072031A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
JP2016034981A5 (https=)
MX2023001219A (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus.
CY1118029T1 (el) Βακτηριοφαγος ή λυτικη πρωτεϊνη που προερχεται απο το βακτηριοφαγο που ειναι αποτελεσματικα για την αντιμετωπιση βιομεμβρανης απο staphylococcus aureus
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
JP2014000092A5 (https=)
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
IN2014DN06652A (https=)
JP2015533791A5 (https=)
MX384834B (es) Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga
WO2016130628A8 (en) Griffithsin mutants
HRP20241279T1 (hr) Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti
MX2016006277A (es) Secuencia de endolisina kz144 modificada.
MY195726A (en) Steviol Glycoside Transport
JP2010265269A5 (https=)
PH12017502323B1 (en) Novel xylanase
EP4043558A3 (en) Kaurenoic acid hydroxylases
JP2019531100A5 (https=)
EA201890232A1 (ru) Новые микроорганизмы и их применение в сельском хозяйстве
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse
JP2015129652A5 (https=)
NZ629093A (en) Monoterpene glycosyltransferase originating from hop and method for using same
WO2017174769A3 (en) Detergent compositions and uses of the same
MY191843A (en) Trehalose phosphorylase